Diagnostics and Therapy for Malignant Tumors

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2025 Jan 8

PMID 39767566

Authors

Chung-Che Tsai

Chun-Yu Wang

Hsu-Hung Chang

Phebe Ting Syuan Chang

Chuan-Hsin Chang

Tin Yi Chu

Po-Chih Hsu

Chan-Yen Kuo

Affiliations

Soon will be listed here.

Abstract

Malignant tumors remain one of the most significant global health challenges and contribute to high mortality rates across various cancer types. The complex nature of these tumors requires multifaceted diagnostic and therapeutic approaches. This review explores current advancements in diagnostic methods, including molecular imaging, biomarkers, and liquid biopsies. It also delves into the evolution of therapeutic strategies, including surgery, chemotherapy, radiation therapy, and novel targeted therapies such as immunotherapy and gene therapy. Although significant progress has been made in the understanding of cancer biology, the future of oncology lies in the integration of precision medicine, improved diagnostic tools, and personalized therapeutic approaches that address tumor heterogeneity. This review aims to provide a comprehensive overview of the current state of cancer diagnostics and treatments while highlighting emerging trends and challenges that lie ahead.

References

Gulilat M, Lamb T, Teft W, Wang J, Dron J, Robinson J . Targeted next generation sequencing as a tool for precision medicine. BMC Med Genomics. 2019; 12(1):81. PMC: 6547602. DOI: 10.1186/s12920-019-0527-2. View

Stavropoulos A, Varras M, Vasilakaki T, Varra V, Tsavari A, Varra F . Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression. Oncol Lett. 2019; 17(5):4575-4589. PMC: 6444490. DOI: 10.3892/ol.2019.10093. View

Konda P, Garinet S, Van Allen E, Viswanathan S . Genome-guided discovery of cancer therapeutic targets. Cell Rep. 2023; 42(8):112978. DOI: 10.1016/j.celrep.2023.112978. View

Fan Q, Cheng Y, Chang H, Deguchi M, Hsueh A, Leung P . Sphingosine-1-phosphate promotes ovarian cancer cell proliferation by disrupting Hippo signaling. Oncotarget. 2017; 8(16):27166-27176. PMC: 5432326. DOI: 10.18632/oncotarget.15677. View

Saeed R, Awan U, Saeed S, Mumtaz S, Akhtar N, Aslam S . Targeted Therapy and Personalized Medicine. Cancer Treat Res. 2023; 185:177-205. DOI: 10.1007/978-3-031-27156-4_10. View

Scholler N, Urban N . CA125 in ovarian cancer. Biomark Med. 2010; 1(4):513-23. PMC: 2872496. DOI: 10.2217/17520363.1.4.513. View

Min H, Lee H . Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022; 54(10):1670-1694. PMC: 9636149. DOI: 10.1038/s12276-022-00864-3. View

Qiu M, Xu Y, Wang J, Zhang E, Sun M, Zheng Y . A novel lncRNA, LUADT1, promotes lung adenocarcinoma proliferation via the epigenetic suppression of p27. Cell Death Dis. 2015; 6:e1858. PMC: 4558496. DOI: 10.1038/cddis.2015.203. View

Fan T, Zhang M, Yang J, Zhu Z, Cao W, Dong C . Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduct Target Ther. 2023; 8(1):450. PMC: 10716479. DOI: 10.1038/s41392-023-01674-3. View

10.

Bulgarelli J, Piccinini C, Petracci E, Pancisi E, Granato A, De Rosa F . Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma. Front Immunol. 2021; 12:778459. PMC: 8578837. DOI: 10.3389/fimmu.2021.778459. View

11.

Xiao M, Xu J, Wang W, Zhang B, Liu J, Li J . Functional significance of cholesterol metabolism in cancer: from threat to treatment. Exp Mol Med. 2023; 55(9):1982-1995. PMC: 10545798. DOI: 10.1038/s12276-023-01079-w. View

12.

Aguissa-Toure A, Li G . Genetic alterations of PTEN in human melanoma. Cell Mol Life Sci. 2011; 69(9):1475-91. PMC: 11114653. DOI: 10.1007/s00018-011-0878-0. View

13.

Butler L, Perone Y, Dehairs J, Lupien L, de Laat V, Talebi A . Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020; 159:245-293. PMC: 7736102. DOI: 10.1016/j.addr.2020.07.013. View

14.

Li A, Bergan R . Clinical trial design: Past, present, and future in the context of big data and precision medicine. Cancer. 2020; 126(22):4838-4846. PMC: 7693060. DOI: 10.1002/cncr.33205. View

15.

Xu M, Qi P, Weng W, Shen X, Ni S, Dong L . Long non-coding RNA LSINCT5 predicts negative prognosis and exhibits oncogenic activity in gastric cancer. Medicine (Baltimore). 2014; 93(28):e303. PMC: 4603127. DOI: 10.1097/MD.0000000000000303. View

16.

Vona R, Iessi E, Matarrese P . Role of Cholesterol and Lipid Rafts in Cancer Signaling: A Promising Therapeutic Opportunity?. Front Cell Dev Biol. 2021; 9:622908. PMC: 8017202. DOI: 10.3389/fcell.2021.622908. View

17.

Sabnis A, Bivona T . Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med. 2019; 25(3):185-197. PMC: 6401263. DOI: 10.1016/j.molmed.2018.12.009. View

18.

Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y . Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int. 2010; 60(5):351-7. DOI: 10.1111/j.1440-1827.2010.02526.x. View

19.

Miller T, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro C . MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008; 283(44):29897-903. PMC: 2573063. DOI: 10.1074/jbc.M804612200. View

20.

Iacoangeli A, Lin Y, Morley E, Muslimov I, Bianchi R, Reilly J . BC200 RNA in invasive and preinvasive breast cancer. Carcinogenesis. 2004; 25(11):2125-33. DOI: 10.1093/carcin/bgh228. View